all report title image

Infectious Disease Diagnostics Market – Insights

Infectious diseases are caused by pathogens such as bacteria, viruses, fungi or parasites. Infectious diseases spread from person to person either through direct contact or indirectly through insect bites or other vectors like food, soil, water, and air. Diagnosis is the identification of disease causing agents by studying the symptoms exhibited by the afflicted individual. It plays a vital role in making decisions regarding accurate treatment of infectious and other diseases.

The global infectious disease diagnostics market is estimated to account for US$ 1,131.4 Mn in terms of value in 2020 and is expected to reach US$ 1,841.2 Mn by the end of 2027.

Global Infectious Disease Diagnostics Market: Drivers

Increasing prevalence of infectious diseases is expected to propel growth of the global infectious disease diagnostics market over the forecast period. For instance, as of February 23, 2020, there were 76,936 reported cases of in mainland China and 1,875 cases of coronavirus disease 2019 in locations outside mainland China and the number of associated deaths was 2,462.

Moreover, funding related to infectious disease diagnostics is also expected to aid in growth of the market. For instance, in January 2018, University of Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid testing in remote locations to help enable rapid diagnosis and rapid treatment of infectious diseases.

Asia Pacific region held dominant position in the global infectious disease diagnostics market in 2018, accounting for 27.0% share in terms of value, followed by Africa.

Infectious Disease Diagnostics  | Coherent Market Insights

Global Infectious Disease Diagnostics Market: Restraints

High price of molecular-based test kits is expected to hinder growth of the market. Molecular-based test kits play a major part in the diagnosis of infectious diseases. However, the high price of molecular test kits is leading to their low adoption, especially in emerging countries.

Lack of reimbursement for certain infectious diseases is also expected to limit growth of the market. For instance, in July 2018, the Centers for Medicare & Medicaid Services significantly reduced reimbursement for evaluation and management of complex cases such as those suffering from infectious diseases.

Global Infectious Disease Diagnostics Market: Opportunities 

Introduction of cost-effective and reliable test kits is expected to offer lucrative growth opportunities for players in the market. Currently, very few effective diagnostic test kits are available for infectious diseases. Unavailability of effective diagnostic tools and high price of existing test kits has triggered the need for cost-effective test kits with high specificity and sensitivity.

Moreover, R&D in diagnostic kits is also expected to aid in growth of the market. For instance, in September 2019, researchers from University of Helsinki, Finland, reported that the antibody response against Puumala orthohantavirus can be measured at a high sensitivity and specificity with the unorthodox point-of-care assay LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection, using urine as sample matrix.

Infectious Disease Diagnostics  | Coherent Market Insights

Diagnostic centers segment in the global infectious disease diagnostics market was valued at US$ 462.1 Mn in 2018 and is expected to reach US$ 958.7 Mn by 2027 at a CAGR of 8.5% during the forecast period.

Market Trends/Key Takeaways

The emphasis on development of point-of-care tests for diagnosis of various infectious diseases is high. Point-of-care tests provide faster results without the sample being sent to diagnostic laboratories for testing. This factor is expected to result in higher demand for point-of-care tests. Companies such as Alere and Cepheid are focusing on developing analytical systems, which provide near patient molecular assay results.

Currently available diagnostic tests are slow and have low specificity and sensitivity. Hence, the market is witnessing a shift from combined tests to rapid diagnostic tests for whole microbial genome sequencing.

Infectious Disease Diagnostics  | Coherent Market Insights

Global Infectious Disease Diagnostics Market: Competitive Landscape

Major players operating in the global infectious disease diagnostics market include, Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.

Global Infectious Disease Diagnostics Market: Key Developments

Major players in the market are focused on launching new services to enhance their market share. For instance, in March 2020, Quest Diagnostics announced to launch a coronavirus (COVID-19) test service that aids the presumptive detection of nucleic acid in respiratory specimens of patients meeting the Centers for Disease Control and Prevention’s clinical criteria for COVID-19 testing.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2020, Thermo Fisher Scientific Inc. announced to acquire QIAGEN N.V., a provider of molecular diagnostics and sample preparation technologies.

Infectious diseases are caused by organisms such as bacteria, viruses, fungi, and parasites and are capable of transmission from one species to another species. Diagnosis of these diseases involves identifying the pathogen and its type and the degree up to which the infection has spread. Infectious diseases such as HIV, tuberculosis, malaria, and Influenza are highly prevalent and can be efficiently diagnosed with the help of diagnostic tests available for the respective diseases. Technologies utilized by these diagnostic tests are classified into biochemical techniques, molecular techniques, immunodiagnostics, and conventional culturing, and staining techniques. Biochemical techniques include ELISA, agglutination, and others, while molecular techniques include Polymerase Chain Reaction (PCR) and Next-Generation Sequencing techniques. These tests are capable of diagnosing the infectious diseases accurately with high throughput capacity.

Restraints of the Global Infectious Disease Diagnostics Market

Factors such as high costs of molecular diagnostic tests, and lack of reimbursement is expected to restrain growth of the market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global infectious disease diagnostics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global infectious disease diagnostics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, Alera Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global infectious disease diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Infectious Disease Diagnostics Market, By Technique:
    • ELISA
    • Polymerase Chain Reaction
    • Immunoassays
    • Cell Cultures
    • Others
  • Global Infectious Disease Diagnostics Market, By Disease Indication:
    • CNS Infection
      • Meningitis
      • Brain Abscess
    • Diarrheal Disease
      • Shigellosis
      • Cholera
      • Enteric/Typhoid Fever
    • Respiratory Infections
      • Tuberculosis
      • Influenza
      • Bronchitis
    • Blood Infections
      • Malaria
      • Dengue
      • Infectious Mononucleosis
      • Others
    • STDs
      • Chlamydia
      • AIDS
      • Syphilis
      • Others
  • Global Infectious Disease Diagnostics Market, By End User:
    • Hospitals
    • Diagnostic Centers
    • Clinics
    • Government Organizations
  • Global Infectious Disease Diagnostics Market, By Geography:
    • North America
      • By Technique
        • ELISA
        • Polymerase Chain Reaction
        • Immunoassays
        • Cell Cultures
        • Others
      • By Disease Indication
        • CNS Infection
          • Meningitis
          • Brain Abscess
        • Diarrheal Disease
          • Shigellosis
          • Cholera
          • Enteric/Typhoid Fever
        • Respiratory Infections
          • Tuberculosis
          • Influenza
          • Bronchitis
        • Blood Infections
          • Malaria
          • Dengue
          • Infectious Mononucleosis
          • Others
        • STDs
          • Chlamydia
          • AIDS
          • Syphilis
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers
        • Clinics
        • Government Organizations
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Technique
        • ELISA
        • Polymerase Chain Reaction
        • Immunoassays
        • Cell Cultures
        • Others
      • By Disease Indication
        • CNS Infection
          • Meningitis
          • Brain Abscess
        • Diarrheal Disease
          • Shigellosis
          • Cholera
          • Enteric/Typhoid Fever
        • Respiratory Infections
          • Tuberculosis
          • Influenza
          • Bronchitis
        • Blood Infections
          • Malaria
          • Dengue
          • Infectious Mononucleosis
          • Others
        • STDs
          • Chlamydia
          • AIDS
          • Syphilis
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers
        • Clinics
        • Government Organizations
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Technique
        • ELISA
        • Polymerase Chain Reaction
        • Immunoassays
        • Cell Cultures
        • Others
      • By Disease Indication
        • CNS Infection
          • Meningitis
          • Brain Abscess
        • Diarrheal Disease
          • Shigellosis
          • Cholera
          • Enteric/Typhoid Fever
        • Respiratory Infections
          • Tuberculosis
          • Influenza
          • Bronchitis
        • Blood Infections
          • Malaria
          • Dengue
          • Infectious Mononucleosis
          • Others
        • STDs
          • Chlamydia
          • AIDS
          • Syphilis
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers
        • Clinics
        • Government Organizations
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Technique
        • ELISA
        • Polymerase Chain Reaction
        • Immunoassays
        • Cell Cultures
        • Others
      • By Disease Indication
        • CNS Infection
          • Meningitis
          • Brain Abscess
        • Diarrheal Disease
          • Shigellosis
          • Cholera
          • Enteric/Typhoid Fever
        • Respiratory Infections
          • Tuberculosis
          • Influenza
          • Bronchitis
        • Blood Infections
          • Malaria
          • Dengue
          • Infectious Mononucleosis
          • Others
        • STDs
          • Chlamydia
          • AIDS
          • Syphilis
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers
        • Clinics
        • Government Organizations
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Technique
        • ELISA
        • Polymerase Chain Reaction
        • Immunoassays
        • Cell Cultures
        • Others
      • By Disease Indication
        • CNS Infection
          • Meningitis
          • Brain Abscess
        • Diarrheal Disease
          • Shigellosis
          • Cholera
          • Enteric/Typhoid Fever
        • Respiratory Infections
          • Tuberculosis
          • Influenza
          • Bronchitis
        • Blood Infections
          • Malaria
          • Dengue
          • Infectious Mononucleosis
          • Others
        • STDs
          • Chlamydia
          • AIDS
          • Syphilis
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers
        • Clinics
        • Government Organizations
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Technique
        • ELISA
        • Polymerase Chain Reaction
        • Immunoassays
        • Cell Cultures
        • Others
      • By Disease Indication
        • CNS Infection
          • Meningitis
          • Brain Abscess
        • Diarrheal Disease
          • Shigellosis
          • Cholera
          • Enteric/Typhoid Fever
        • Respiratory Infections
          • Tuberculosis
          • Influenza
          • Bronchitis
        • Blood Infections
          • Malaria
          • Dengue
          • Infectious Mononucleosis
          • Others
        • STDs
          • Chlamydia
          • AIDS
          • Syphilis
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers
        • Clinics
        • Government Organizations
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Becton Dickinson & Company *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Cepheid, Inc.
    • Abbott Laboratories
    • BioMerieux SA
    • Hologic, Inc.
    • Danaher Corporation
    • Thermo Fisher Scientific, Inc.
    • Roche Diagnostics
    • DiaSorin S.p.A.
    • Quidel Corporation
    • Bio-Rad Laboratories, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global infectious disease diagnostics market is estimated to surpass US$ 1,841.2 Million by 2027
Major players operating in the global infectious disease diagnostics market include Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
High price of molecular-based test kits is one of the major factors that is expected to hamper growth of the market over the forecast period.
Increasing prevalence of infectious diseases is one of the major factors that is expected to propel growth of the market over the forecast period.
Among disease indications, STDs segment held dominant position in the global infectious disease diagnostics market in 2018, accounting for 32.8% share in terms of value, followed by CNS infection, and respiratory infections, respectively.
Among regions, Asia Pacific held dominant position in the global infectious disease diagnostics market in 2018, accounting for 27.0% share, in terms of value, followed by Africa.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo